Improvement of exercise tolerance by a long-term assisting use of the short acting beta 2 agonist (procaterol) for pulmonary rehabilitation in patients with COPD.

Improvement of exercise tolerance by a long-term assisting use of the short acting beta 2 agonist (procaterol) for pulmonary rehabilitation in patients with COPD. - Assisting use of procaterol for pulmonary rehabilitation in patients with COPD.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009577

Enrollment

120

Registered

2013-01-02

Start date

2013-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Single inhalation of procaterol hydrochloride 20 microgram and pulmonary rehabilitation Pulmonary rehabilitation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The COPD patients above the severity of moderate (GOLD 2) in stable phase, who recruited from in-outpatients and still have dyspnea on exertion despite therapy with long-acting bronchodilators.

Exclusion criteria

Exclusion criteria: The patients who considered to have risks for exercise test, such as coronary vascular disease, arrhythmia, and heart failure are excluded from this study.

Design outcomes

Primary

Measure	Time frame
Endurance shuttle walking test ;ESWT	—

Secondary

Measure	Time frame
Pulmonary Function Test Borg CR-10(Category-Ratio 10) SpO2, HR Nagasaki University Respiratory ADL Questionnaire St. George's Respiratory Questionnaire	—

Countries

Japan

Contacts

Public ContactHajime Kurosawa

Tohoku University Graduate School of Medicine Department of Occupational Health

022-717-7874

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026